![](https://www.diabetesnews.com/wp-content/uploads/2014/06/insulin-1-3c0e963869bf5abd8a8bba77ccf1818be51f46ac-s40-c85-150x150.jpg)
For patients with impaired glucose tolerance or early diabetes, use of insulin glargine (Lantus) was the best predictor of maintaining a lower hemoglobin A1c (HbA1c) level over 5 years, according to a subanalysis of the ORIGIN trial.
For patients with impaired glucose tolerance or early diabetes, use of insulin glargine (Lantus) was the best predictor of maintaining a lower hemoglobin A1c (HbA1c) level over 5 years, according to a subanalysis of the ORIGIN trial.